About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Texas | 1,334 Studies

Clinical Trials Lung CancerTexas

Lung Cancer Clinical Trials in Texas

Find 1,334 clinical trials for lung cancer near Texas. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Texas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 1,334 trials

CompletedCombination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCEvaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.NCT03625323·Huston, Texas Active not recruitingIntravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseThis phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with…NCT03025256·Houston, Texas CompletedErlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLCThis will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway.NCT00294762·Alhambra, California and 42 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedStudy of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients.NCT03580694·Chicago, Illinois and 5 others

CompletedA Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesThis is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of…NCT03629756·Scottsdale, Arizona and 14 others

RecruitingStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably.NCT05005403·Duarte, California and 47 others

UnknownDocetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung CancerRATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.NCT00030641·Birmingham, Alabama and 43 others

CompletedA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus…NCT04623775·Duarte, California and 124 others

CompletedA Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksThe primary objective of this study is to compare PFS (progression-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks with…NCT02713867·Birmingham, Alabama and 128 others

TerminatedA Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentThe main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in…NCT04933695·Birmingham, Alabama and 66 others

RecruitingVMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaThis is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or…NCT03556228·Santa Rosa, California and 14 others

RecruitingStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsThis study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated…NCT06128551·Duarte, California and 55 others

Active not recruitingA Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesThe primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for…NCT06120075·Denver, Colorado and 9 others

CompletedA Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsThis is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic…NCT03000257·La Jolla, California and 25 others

Active not recruitingPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy.NCT03944772·Duarte, California and 46 others

CompletedPemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer.NCT00071136·Fort Myers, Florida and 4 others

TerminatedTusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEAThis is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous…NCT05245071·Buffalo, New York and 34 others

Active not recruitingA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursThis is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and…NCT06147037·Palo Alto, California and 7 others

TerminatedTIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed TherapyThe purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not…NCT02186301·Birmingham, Alabama and 73 others

CompletedA Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.NCT03516981·Tempe, Arizona and 80 others

Page 1 of 67Next

Other Conditions in Texas

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma